AB278172

Immune Checkpoint Inhibitors Panel - Human WB

Recombinant
What is this?

Be the first to review this product! Submit a review

(0 Publication)

Immune Checkpoint Inhibitors Panel - Human WB (ab278172) is part of our antibody panels range. Abcam offers high-quality biological reagents and tools including antibodies, proteins, assays, cell lines and lysates.

View Alternative Names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD366, TIM3, TIMD3, HAVCR2, Hepatitis A virus cellular receptor 2, HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3, T-cell immunoglobulin mucin receptor 3, T-cell membrane protein 3, TIMD-3, TIM-3, CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1, CD273, B7DC, PDCD1L2, PDL2, PDCD1LG2, Programmed cell death 1 ligand 2, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2, Butyrophilin B7-DC, B7-DC, CD223, FDC, LAG3, Lymphocyte activation gene 3 protein, LAG-3, CD152, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, VSIG9, VSTM3, TIGIT, T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, C10orf54, SISP1, VISTA, PP2135, UNQ730/PRO1412, VSIR, V-type immunoglobulin domain-containing suppressor of T-cell activation, Platelet receptor Gi24, Stress-induced secreted protein-1, V-set domain-containing immunoregulatory receptor, V-set immunoregulatory receptor, Sisp-1

10 Images

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-PD-L2 antibody [CAL28] (ab256386) at 1/1000 dilution

Lane 1 : HDLM-2 (Human Hodgkin lymphoma) whole cell lysate 20 μg
Lane 2 : Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate 20 μg

Secondary : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution (all lanes)

Predicted band size : 31 kDa
Observed band size : 45-60 kDa

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 10 seconds.

Negative control : Jurkat. (PMID : 27631416).

false

Exposure time: 10s

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-CTLA4 antibody [CAL49] (ab237712) at 1/1000 dilution.

Lane 1 : Untreated human PBMC (human peripheral blood mononuclear cell) whole cell lysate, 20 ug.

Lane 2 : Human PBMC (treated with 10μg/ml PHA for 2 days) whole cell lysate, 20 ug.

Lane 3 : Untreated mouse splenocyte whole cell lysate, 20 ug.

Lane 4 : Mouse splenocyte (treated with 2.5μg/ml Concanavalin A (ConA) for 3 days) whole cell lysate, 20 ug.

Secondary (all lanes) : ab97051 at 1/100000 dilution.

Predicted MW : 25 kDa.

Observed MW : 25 kDa.

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 3 minutes.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-LAG-3 antibody [EPR20261] (ab209236) at 1/1000 dilution.

Lane 1 : Human LAG3 Fc chimera recombinant protein (aa23-450), 0.01 ug.

Secondary (all lanes) : ab97051 at 1/100000 dilution.

Predicted MW : 57 kDa.

Observed MW : 90 kDa.

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 1 second.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-PD-L1 antibody [73-10] (ab228415) at 1/1000 dilution.

Lane 1 : MDA-MB-231 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 2 : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 3 : SK-BR-3 (Human breast adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 4 : H1975 (Human non-small cell lung cancer epithelial cell) whole cell lysate, 20 ug.
Lane 5 : NCI-H1299 (Human lung carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 6 : A549 (Human lung carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 7 : SW480 (Human colorectal adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 8 : HCT 116 (Human colorectal carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 9 : PC-3 (Human prostate adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 10 : DU 145 (Human prostate carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 11 : A375 (Human malignant melanoma epithelial cell) whole cell lysate, 20 ug.
Lane 12 : MeWo (Human malignant melanoma fibroblast) whole cell lysate, 20 ug.
Lane 13 : U-87 MG (Human glioblastoma-astrocytoma epithelial cell) whole cell lysate, 20 ug.
Lane 14 : Huh7 (Human hepatocellular carcinoma epithelial cell) whole cell lysate, 20 ug.

Lane 15 : HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 16 : BXPC-3 (Human pancreas adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 17 : PANC-1 (Human pancreatic epithelioid carcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 18 : NIH : OVCAR-3 (Human ovary adenocarcinoma epithelial cell) whole cell lysate, 20 ug.
Lane 19 : SK-OV-3 (Human ovarian cancer epithelial cell) whole cell lysate, 20 ug.
Lane 20 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate, 20 ug.

Secondary (all lanes) : ab97051 at 1/20000 dilution.

Predicted MW : 33 kDa.

Observed MW : 40-60kDa.

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 120 seconds.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-PD-L1 antibody [73-10] (ab228415) at 1/1000 dilution.

Lane 1 : NCI-H1975 (human non-small cell lung cancer cell line), whole cell lysate, 20 ug.

Lane 2 : Human placenta, 20 ug.

Lane 3 : Human thymus, 20 ug.

Secondary (all lanes) : ab97051 at 1/50000 dilution.

Predicted MW : 33 kDa.

Observed MW : The molecular mass observed is consistent with what has been described in the literature (PMID : 26546452).

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 70 seconds.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-TIM 3 antibody [EPR22241] (ab241332) at 1/1000 dilution.

Lane 1 : Daudi (human Burkitt's lymphoma cell line) whole cell lysate, 20 ug.

Lane 2 : Daudi whole cell lysate (treated with PNGase F), 20 mg/ml.

Lane 3 : RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate, 20 ug.

Lane 4 : RAW 264.7 whole cell lysate (treated with PNGase F), 20 ug.

Secondary (all lanes) : ab97051 at 1/20000 dilution.

Predicted MW : 33 kDa.

Observed MW : 40 kDa, 50-60kDa (glycosylated form)

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 70 seconds. Lanes 3 & 4 were developed using a higher sensitivity ECL substrate.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-VISTA antibody [EPR21050] (ab230950) at 1/1000 dilution.

Lane 1 : Human fetal spleen lysate, 20 ug.

Lane 2 : Human thymus lysate, 20 ug.

Lane 3 : DU145 (Human prostate carcinoma epithelial cell) whole cell lysate, 20 ug.

Lane 4 : Human fetal lung lysate, 20 ug.

Secondary (all lanes) : ab97051 at 1/20000 dilution.

Predicted MW : 34 kDa.

Observed MW : The 50-60 kda band observed is the glycosylated form of VISTA, consistent with what has been described in the literature (PMID : 29216931).

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : Lanes 1-2 : 32 seconds; Lanes 3-4 : 6 seconds.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-TIGIT antibody [BLR047F] - BSA free (ab243903) at 1/1000 dilution.

Lane 1 : HeLa cell whole cell lysate, 50 ug.

Lane 2 : HEK-293T cell whole cell lysate, 50 ug.

Lane 3 : MyLa CD4+ whole cell lysate, 50 ug.

Lane 4 : HepG2 whole cell lysate, 50 ug.

Lane 5 : MG whole cell lysate, 50 μg.

Lane 6 : Jurkat whole cell lysate, 50 μg.

Lane 7 : GaMG whole cell lysate, 50 μg.

Lane 8 : A549 whole cell lysate, 50 μg.

Secondary (all lanes) : HRP-conjugated goat anti-rabbit IgG antibody.

Predicted MW : 26 kDa.

Exposure time : 3 minutes.

Detection : chemiluminescence

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-PD1 antibody [EPR23119-111] (ab243644) at 1/1000 dilution.

Lane 1 : Human tonsil tissue lysate, 20 ug.

Lane 2 : Human tonsil tissue lysate treated with PNGase F, 20 ug.

Secondary (all lanes) : ab131366 at 1/1000 dilution

Predicted MW : 32 kDa.

Observed MW : 50-55kDa. The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 30487606, 31783892).

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 48 seconds. This blot was developed using a higher sensitivity ECL substrate.

false

Supplier Data

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

All lanes : Anti-PD1 antibody [EPR23119-111] (ab243644) at 1/1000 dilution.

Lane 1 : Untreated MOLT-4 (human lymphoblastic leukemia T lymphoblast), 20 ug.

Lane 2 : MOLT-4 treated with 500ng/ml Ionomycin and 10ng/ml Phorbol-12-myristate-13-acetate (PMA) for 24 hours, 20 ug.

Secondary (all lanes) : ab131366 at 1/1000 dilution

Predicted MW : 32 kDa.

Observed MW : 50-55kDa. The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID : 30487606, 31783892).

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 48 seconds. This blot was developed using a higher sensitivity ECL substrate.

false

Key facts

Reacts with

Human

Target

CD274

target

style

left-column

style

left-column

Product details

Immune Checkpoint Inhibitors Panel - Human WB ab278172 contains multiple trial-sized versions of anti-human antibody clones against PD-L1, PD-L2, PD1, LAG3, TIM 3, VISTA, CTLA4 and TIGIT specifically selected for high performance in various applications. They are provided as a sampler panel to allow you to easily evaluate each antibody.

For guidelines on how to use each antibody within the panel, please consult the individual datasheet for each antibody.

Panel contains:

- Rabbit monoclonal [73-10] to PD-L1 (20 μL) ab228415

- Rabbit monoclonal [CAL28] to PD-L2 (20 μL) ab256386

- Rabbit monoclonal [EPR23119-111] to PD1 (20 μL) ab243644

- Rabbit monoclonal [EPR20261] to LAG-3 (20 μL) ab209236

- Rabbit monoclonal [EPR22241] to TIM 3 (20 μL) ab241332

- Rabbit monoclonal [EPR21050] to VISTA (20 μL) ab230950

- Rabbit monoclonal [CAL49] to CTLA4 (20 μL) ab237712

- Rabbit monoclonal [BLR047F] to TIGIT - BSA free (20 μL) ab243903

Explore our range of antibody sample panels designed to provide you with a variety of trial-size antibodies in a convenient and cost-effective format.

Carrier-free formulations of our recombinant antibodies are also available for easy conjugation to labels of your choice and for multiplex applications. Use our intuitive search and select carrier-free or your label of choice. For bespoke conjugations or large volumes email bespoke@abcam.com.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

style

left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab278172-1Kit", "assetComponentDetails": [ { "size":"2 x 10 µL", "name":"Anti-PD-L2 antibody [CAL28]", "number":"AB278172-CMP09", "productcode":"AB256386" }, { "size":"2 x 10 µL", "name":"Anti-Lymphocyte Activation Gene 3 antibody [EPR20261]", "number":"AB278172-CMP02", "productcode":"AB209236" }, { "size":"2 x 10 µL", "name":"Anti-TIM 3 antibody [EPR22241]", "number":"AB278172-CMP06", "productcode":"AB241332" }, { "size":"2 x 10 µL", "name":"Anti-PD-L1 antibody [73-10]", "number":"AB278172-CMP05", "productcode":"AB228415" }, { "size":"2 x 10 µL", "name":"Anti-CTLA4 antibody [CAL49]", "number":"AB278172-CMP07", "productcode":"AB237712" }, { "size":"2 x 10 µL", "name":"Anti-PD1 antibody [EPR23119-111]", "number":"AB278172-CMP03", "productcode":"AB243644" }, { "size":"2 x 10 µL", "name":"Anti-TIGIT antibody [BLR047F]", "number":"AB278172-CMP01", "productcode":"AB243903" }, { "size":"2 x 10 µL", "name":"Anti-VISTA antibody [EPR21050]", "number":"AB278172-CMP04", "productcode":"AB230950" } ] } } }

style

left-column

Properties and storage information

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

-20°C

Appropriate long-term storage conditions

-20°C

Storage information

-20°C

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CTLA4 TIM-3 PD-L2 PD1 LAG-3 PD-L1 VISTA and TIGIT are co-inhibitory receptors involved in immune regulation. These proteins regulate T cell responses and tolerance by delivering inhibitory signals that down-modulate effector functions. For example CTLA4 sometimes called CD152 is a 33 kDa protein expressed on regulatory T cells and activated conventional T cells. PD-1 known as PDCD1 is a 55 kDa protein expressed on activated T cells B cells and myeloid cells. These proteins localize mainly at the immune synapse and influence immune signaling pathways.

Biological function summary

These proteins play critical roles in the immune system. They form complexes that send signals to T cells to reduce their activity preventing overactivation that can lead to autoimmune conditions. TIM-3 is particularly involved in inhibiting T cell responses and is expressed on Th1 and cytotoxic T cells. PD-L1 the ligand for PD-1 can be found on antigen-presenting cells and some tumor cells also contributing to immune evasion by tumors.

Pathways

These receptors participate in multiple signaling pathways key to maintaining immune homeostasis. The PD-1/PD-L1 pathway modulates T cell activity during antigen presentation significantly impacting pathways related to immune tolerance. CTLA4 interacts with the CD28 receptor pathway providing a checkpoint in immune activation. These interactions often involve proteins such as B7-1 and B7-2 which are costimulatory molecules that further regulate immune responses.

These proteins have associations with autoimmune diseases and cancer. Dysregulation of CTLA4 for instance links to autoimmune disorders like rheumatoid arthritis. PD1 and PD-L1 have roles in cancer because tumors often exploit these pathways to avoid immune detection. Inhibition of these checkpoint proteins with therapeutic antibodies has shown promise in cancer treatment. Studies also highlight interactions with proteins such as CD28 and PD1 essential factors in understanding their roles in immune evasion and disease progression.

style

left-column

Product protocols

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

See full target information CD274

Additional targets

PDCD1LG2,PDCD1,LAG3,HAVCR2,VSIR,CTLA4,TIGIT

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Immune Checkpoint Inhibitors Panel - Human WB

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Western blot - Immune Checkpoint Inhibitors Panel - Human WB (AB278172)

Key facts

Reacts with

Target

Complementary Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product details

What's included?

Properties and storage information

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Additional targets

Product promise